JP2021520380A - ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法 - Google Patents

ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法 Download PDF

Info

Publication number
JP2021520380A
JP2021520380A JP2020554275A JP2020554275A JP2021520380A JP 2021520380 A JP2021520380 A JP 2021520380A JP 2020554275 A JP2020554275 A JP 2020554275A JP 2020554275 A JP2020554275 A JP 2020554275A JP 2021520380 A JP2021520380 A JP 2021520380A
Authority
JP
Japan
Prior art keywords
msc
hct
months
cells
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520380A5 (https=
Inventor
ジョアン カーツバーグ，
ジョアン カーツバーグ，
ジェラルディン ドーソン，
ジェラルディン ドーソン，
ジェシカ サン，
ジェシカ サン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68101425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2021520380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Publication of JP2021520380A publication Critical patent/JP2021520380A/ja
Publication of JP2021520380A5 publication Critical patent/JP2021520380A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
JP2020554275A 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法 Pending JP2021520380A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
US62/652,722 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (2)

Publication Number Publication Date
JP2021520380A true JP2021520380A (ja) 2021-08-19
JP2021520380A5 JP2021520380A5 (https=) 2022-04-11

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554275A Pending JP2021520380A (ja) 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Study NCT03099239 on Date: March 15, 2018(v8)", CLINICALTRIALS.GOV ARCHIVE[ONLINE], vol. [2023年1月17日検索], JPN6023002140, 15 March 2018 (2018-03-15), ISSN: 0005117021 *
CYTOTHERAPY, vol. 19, JPN6023002142, 2017, pages 1351 - 1382, ISSN: 0005117022 *
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11, JPN6023002141, 2013, pages 196, ISSN: 0005117020 *
STEM CELLS TRANSLATIONAL MEDICINE, vol. 6, JPN6023002139, 2017, pages 1332 - 1339, ISSN: 0004969352 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Also Published As

Publication number Publication date
CA3096033A1 (en) 2019-10-10
EP3773486A1 (en) 2021-02-17
BR112020020295A2 (pt) 2021-01-12
IL277733B1 (en) 2024-06-01
AU2019247210A1 (en) 2020-11-05
EP3773486B1 (en) 2023-12-06
IL277733A (en) 2020-11-30
US20210128631A1 (en) 2021-05-06
SG11202009805PA (en) 2020-11-27
IL277733B2 (en) 2024-10-01
US12491210B2 (en) 2025-12-09
KR20210031853A (ko) 2021-03-23
WO2019195506A1 (en) 2019-10-10
ES2968823T3 (es) 2024-05-14
CN112351785A (zh) 2021-02-09
EP3773486A4 (en) 2021-12-15
EP3773486C0 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Mohammadzadeh et al. Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial-the COPSYCH study protocol
US12491210B2 (en) Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
Tai-MacArthur et al. The theoretical basis of in utero hematopoietic stem cell transplantation and its use in the treatment of blood disorders
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Akhlaghpasand et al. Repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells for spastic cerebral palsy: Single-arm safety and preliminary efficacy clinical trial
Wong et al. Autologous umbilical cord blood infusion for the treatment of autism in young children: A within‐subjects open label study on safety (assessed via caregiver report) and efficacy
Shamim et al. The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder
Harvey et al. Cognition in severe mental illness
Abubakar et al. Neurological uniqueness: a case study of Hepatitis A-Induced Acute Inflammatory demyelinating polyneuropathy
Gesundheit et al. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report
Saitoh et al. Safety and feasibility of allogeneic sibling cord blood infusion in Japanese children with cerebral palsy: A single-center pilot study
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Ahmed et al. Iron Deficiency Anemia among Children with Febrile Seizures Presenting at CMH Muzaffarabad
Aburto et al. Uneven state distribution of homicides in Brazil and their effect on life expectancy, 2000-2015
Gauthier Mesenchymal Stem Cell Transplantation: A Novel Approach to Treating Progressive Neurological Diseases
Babinski Allogeneic Mesenchymal Stromal Cell Infusions Are Safe and Effective in Children with Autism Spectrum
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Paul Eighth Annual Huntington Disease Clinical Research Symposium
Ebomoyi Neonatal screening for sickle cell disease, caveats about potential cure with innovative medical technology and the relevant evidence-based health education

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230728